{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:56:47Z","timestamp":1791021407777,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>BRAF and MEK inhibitors are used to treat a range of paediatric tumours including low-grade gliomas. The ubiquitous nature of the BRAF\/MAPK\/MEK pathway means such treatments are not without side effects such as renal tubulopathies and hyperglycaemia. This study aims to describe the endocrine dysfunction observed in a cohort of children treated with BRAF and MEK inhibitors at the largest paediatric centre in the UK utilising these treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Electronic data for patients treated with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) from January 2019 to May 2022 were retrospectively reviewed. Outcomes included diagnosis of glucose dysregulation, the presence of hyponatraemia (&lt;\u2009135 mmol\/l) and sodium nadir during treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 55 patients were included for analysis. Nine patients had at least one hyponatraemic episode during treatment of whom three had coexisting central diabetes insipidus. A statistically significant difference (p-value\u2009=\u20090.037) with regards to the plasma sodium nadir during treatment was observed between patients with diabetes insipidus (median\u2009=\u2009134 (132\u2013137) mmol\/l) and patients without (median\u2009=\u2009137 (127\u2013141 mmol\/l). Six patients were diagnosed with a form of glucose dysregulation (e.g. insulin resistance, type 2 diabetes), of whom four were diagnosed during treatment with dabrafenib, all with hypothalamo-pituitary lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Clinicians using such treatments need to be aware of these potential effects, particularly the risk of hyponatraemia in patients with pre-existing central diabetes insipidus and monitor for these accordingly, including performing measurements of sodium and glucose prior to, during and after treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11060-024-04896-9","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T09:51:10Z","timestamp":1734083470000},"page":"257-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Endocrine effects of MEK and BRAF inhibitor therapy in paediatric patients: a tertiary centre experience"],"prefix":"10.1007","volume":"172","author":[{"given":"Arif Hanafi Bin","family":"Jalal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buddhi","family":"Gunasekara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-0397","authenticated-orcid":false,"given":"Hoong-Wei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"issue":"22","key":"4896_CR1","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1002\/cncr.28864","volume":"120","author":"M Burotto","year":"2014","unstructured":"Burotto M, Chiou VL, Lee JM, Kohn EC (2014) The MAPK pathway across different malignancies: a new perspective. Cancer 120(22):3446\u20133456 Epub 2014\/06\/21. https:\/\/doi.org\/10.1002\/cncr.28864","journal-title":"Cancer"},{"issue":"9992","key":"4896_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/s0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386(9992):444\u2013451 Epub 2015\/06\/04. https:\/\/doi.org\/10.1016\/s0140-6736(15)60898-4","journal-title":"Lancet"},{"issue":"5","key":"4896_CR3","first-page":"100324","volume":"3","author":"BE Johnson","year":"2022","unstructured":"Johnson BE, Baik CS, Mazieres J, Groen HJM, Melosky B, Wolf J et al (2022) Clinical outcomes with Dabrafenib Plus Trametinib in a clinical trial Versus Real-World Standard of Care in patients with BRAF-Mutated Advanced NSCLC. JTO Clin Res Rep 3(5):100324 PubMed PMID: 35592617; PubMed Central PMCID: PMC9112112","journal-title":"JTO Clin Res Rep"},{"key":"4896_CR4","unstructured":"PHE (2021) Children, teenagers and young adults UK cancer statistics report 2021"},{"issue":"3","key":"4896_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11060-014-1673-1","volume":"121","author":"CR Nwachukwu","year":"2015","unstructured":"Nwachukwu CR, Youland RS, Chioreso C, Wetjen N, NageswaraRao A, Keating G et al (2015) Health related quality of life (HRQOL) in long-term survivors of pediatric low grade gliomas (LGGs). J Neurooncol 121(3):599\u2013607 Epub 2014\/12\/04. https:\/\/doi.org\/10.1007\/s11060-014-1673-1","journal-title":"J Neurooncol"},{"issue":"8","key":"4896_CR6","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/cncr.29907","volume":"122","author":"R Krishnatry","year":"2016","unstructured":"Krishnatry R, Zhukova N, Guerreiro Stucklin AS, Pole JD, Mistry M, Fried I et al (2016) Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer 122(8):1261\u20131269 Epub 2016\/03\/13. https:\/\/doi.org\/10.1002\/cncr.29907","journal-title":"Cancer"},{"issue":"6","key":"4896_CR7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1593\/tlo.12328","volume":"5","author":"JK Myung","year":"2012","unstructured":"Myung JK, Cho H, Park CK, Kim SK, Lee SH, Park SH (2012) Analysis of the BRAF(V600E) mutation in Central Nervous System tumors. Transl Oncol 5(6):430\u2013436 Epub 2013\/01\/17. https:\/\/doi.org\/10.1593\/tlo.12328","journal-title":"Transl Oncol"},{"issue":"11","key":"4896_CR8","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML et al (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116(11):1919\u20131923 Epub 2010\/06\/04. https:\/\/doi.org\/10.1182\/blood-2010-04-279083","journal-title":"Blood"},{"issue":"7","key":"4896_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/neuonc\/noq007","volume":"12","author":"MJ Dougherty","year":"2010","unstructured":"Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ et al (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 12(7):621\u2013630 Epub 2010\/02\/17. https:\/\/doi.org\/10.1093\/neuonc\/noq007","journal-title":"Neuro Oncol"},{"issue":"7074","key":"4896_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature04304","volume":"439","author":"DB Solit","year":"2006","unstructured":"Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439(7074):358\u2013362 Epub 2005\/11\/08. https:\/\/doi.org\/10.1038\/nature04304","journal-title":"Nature"},{"issue":"24","key":"4896_CR11","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.1158\/1078-0432.Ccr-19-2177","volume":"25","author":"DR Hargrave","year":"2019","unstructured":"Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR et al (2019) Efficacy and safety of Dabrafenib in Pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-Grade Glioma: results from a phase I\/IIa study. Clin Cancer Res 25(24):7303\u20137311 Epub 2019\/12\/08. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2177","journal-title":"Clin Cancer Res"},{"issue":"24","key":"4896_CR12","doi-asserted-by":"publisher","first-page":"7294","DOI":"10.1158\/1078-0432.Ccr-17-3572","volume":"25","author":"MW Kieran","year":"2019","unstructured":"Kieran MW, Geoerger B, Dunkel IJ, Broniscer A, Hargrave D, Hingorani P et al (2019) A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors. Clin Cancer Res 25(24):7294\u20137302 Epub 2019\/09\/12. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-3572","journal-title":"Clin Cancer Res"},{"key":"4896_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac109","author":"AM Gross","year":"2022","unstructured":"Gross AM, Glassberg B, Wolters PL, Dombi E, Baldwin A, Fisher MJ et al (2022) Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform Neurofibroma at risk for developing tumor-related morbidity. Neuro Oncol. Epub 2022\/04\/26 https:\/\/doi.org\/10.1093\/neuonc\/noac109","journal-title":"Neuro Oncol"},{"issue":"1","key":"4896_CR14","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","volume":"19","author":"S Perreault","year":"2019","unstructured":"Perreault S, Larouche V, Tabori U, Hawkin C, Lipp\u00e9 S, Ellezam B et al (2019) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01. BMC Cancer 19(1):1250 Epub 2019\/12\/29. https:\/\/doi.org\/10.1186\/s12885-019-6442-2","journal-title":"BMC Cancer"},{"issue":"Supplement4","key":"4896_CR15","doi-asserted-by":"publisher","first-page":"iv9","DOI":"10.1093\/noajnl\/vdab112.032","volume":"3","author":"S Perreault","year":"2021","unstructured":"Perreault S, Larouche V, Tabori U, Hawkins C, Lipp\u00e9 S, Ellezam B, PHASE 2 STUDY OF TRAMETINIB FOR PATIENTS WITH PEDIATRIC GLIOMA WITH ACTIVATION OF THE MAPK\/ERK PATHWAY (2021) SYST-04. TRAM-01: A. Neuro-Oncology Adv 3(Supplement4):iv9\u2013iv. https:\/\/doi.org\/10.1093\/noajnl\/vdab112.032","journal-title":"Neuro-Oncology Adv"},{"key":"4896_CR16","unstructured":"FDA (2022) MEKINIST\u00ae (trametinib) tablets, for oral use"},{"issue":"2","key":"4896_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1758834014566428","volume":"7","author":"SJ Welsh","year":"2015","unstructured":"Welsh SJ, Corrie PG (2015) Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 7(2):122\u2013136 Epub 2015\/03\/11. doi: 10.1177\/1758834014566428. PubMed PMID: 25755684; PubMed Central PMCID: PMC4346212","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"4896_CR18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/thy.2022.0115","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, DeSouza JA, Poi M, Seligson ND, Cabanillas ME, Sipos JA, Ringel MD, Eisfeld AK, Timmers C, Shah MH (2022) Dabrafenib Versus Dabrafenib\u2009+\u2009Trametinib in BRAF-Mutated Radioactive Iodine Refractory differentiated thyroid Cancer: results of a Randomized, phase 2, open-label Multicenter Trial. Thyroid 32(10):1184\u20131192. https:\/\/doi.org\/10.1089\/thy.2022.0115Epub 2022 Jul 5. PMID: 35658604; PMCID: PMC9595631. We believe we have corrected this as requested","journal-title":"Thyroid"},{"key":"4896_CR19","unstructured":"Gan HW, Cerbone M, Bulwer C, Spoudeas HA (2000) Pituitary and Hypothalamic Tumor syndromes in Childhood. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K et al (eds) Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright \u00a9 2000\u20132022. MDText.com, Inc."},{"issue":"4","key":"4896_CR20","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1097\/mph.0000000000001427","volume":"42","author":"G Egan","year":"2020","unstructured":"Egan G, Hamilton J, McKeown T, Bouffet E, Tabori U, Dirks P et al (2020) Trametinib toxicities in patients with low-grade gliomas and diabetes insipidus: related findings? J Pediatr Hematol Oncol 42(4):e248\u2013e50 Epub 2019\/01\/25. https:\/\/doi.org\/10.1097\/mph.0000000000001427","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"4896_CR21","doi-asserted-by":"publisher","first-page":"e550","DOI":"10.1097\/mph.0000000000001859","volume":"43","author":"MA Lazow","year":"2021","unstructured":"Lazow MA, Lawson SA, Salloum R, Hummel TR, Pillay Smiley N, DeWire-Schottmiller MD et al (2021) Trametinib-associated hyponatremia in a child with low-grade glioma is not seen following treatment with Alternative MEK inhibitor. J Pediatr Hematol Oncol 43(4):e550\u2013e3 Epub 2020\/06\/11. https:\/\/doi.org\/10.1097\/mph.0000000000001859","journal-title":"J Pediatr Hematol Oncol"},{"key":"4896_CR22","unstructured":"World Health Organization, International Diabetes Federation (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO\/IDF consultation"},{"issue":"2","key":"4896_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00592-015-0782-4","volume":"53","author":"B Shashaj","year":"2016","unstructured":"Shashaj B, Luciano R, Contoli B, Morino GS, Spreghini MR, Rustico C et al (2016) Reference ranges of HOMA-IR in normal-weight and obese young caucasians. Acta Diabetol 53(2):251\u2013260 Epub 20150613. https:\/\/doi.org\/10.1007\/s00592-015-0782-4","journal-title":"Acta Diabetol"},{"issue":"8","key":"4896_CR24","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/eye.2015.82","volume":"29","author":"KE Duncan","year":"2015","unstructured":"Duncan KE, Chang LY, Patronas M (2015) MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity. Eye (Lond) 29(8):1003\u20131012 Epub 20150605. doi: 10.1038\/eye.2015.82. PubMed PMID: 26043707; PubMed Central PMCID: PMC4541356","journal-title":"Eye (Lond)"},{"key":"4896_CR25","doi-asserted-by":"publisher","unstructured":"Jiang Q, Cao C, Lu S, Kivlin R, Wallin B, Chu W et al (2009) MEK\/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med.; 23(6):771-7. https:\/\/doi.org\/10.3892\/ijmm_00000191. PubMed PMID: 19424603","DOI":"10.3892\/ijmm_00000191"},{"issue":"18","key":"4896_CR26","doi-asserted-by":"publisher","first-page":"15765","DOI":"10.1074\/jbc.M209980200","volume":"278","author":"F Umenishi","year":"2003","unstructured":"Umenishi F, Schrier RW (2003) Hypertonicity-induced aquaporin-1 (AQP1) expression is mediated by the activation of MAPK pathways and hypertonicity-responsive element in the AQP1 gene. J Biol Chem 278(18):15765\u201315770 Epub 20030221. https:\/\/doi.org\/10.1074\/jbc.M209980200","journal-title":"J Biol Chem"},{"issue":"39","key":"4896_CR27","doi-asserted-by":"publisher","first-page":"26643","DOI":"10.1074\/jbc.M801071200","volume":"283","author":"U Hasler","year":"2008","unstructured":"Hasler U, Nunes P, Bouley R, Lu HA, Matsuzaki T, Brown D (2008) Acute hypertonicity alters aquaporin-2 trafficking and induces a MAPK-dependent accumulation at the plasma membrane of renal epithelial cells. J Biol Chem 283(39):26643\u201326661 Epub 20080729. https:\/\/doi.org\/10.1074\/jbc.M801071200","journal-title":"J Biol Chem"},{"issue":"8","key":"4896_CR28","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1073\/pnas.0910646107","volume":"107","author":"MM Rinschen","year":"2010","unstructured":"Rinschen MM, Yu MJ, Wang G, Boja ES, Hoffert JD, Pisitkun T et al (2010) Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci U S A 107(8):3882\u20133887 Epub 20100205. https:\/\/doi.org\/10.1073\/pnas.0910646107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4896_CR29","doi-asserted-by":"crossref","unstructured":"Gunasekara B, Gunn H, Wei GH (eds) (2022) Trametinib induced hyponatraemia in a patient with craniopharyngioma and diabetes insipidus. Endocrine Abstracts","DOI":"10.1530\/endoabs.85.P29"},{"key":"4896_CR30","unstructured":"De Meyts P (2000) The insulin receptor and its Signal Transduction Network. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K et al (eds) Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright \u00a9 2000\u20132022. MDText.com, Inc."},{"issue":"1","key":"4896_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/2191-219x-2-22","volume":"2","author":"AR Baudy","year":"2012","unstructured":"Baudy AR, Dogan T, Flores-Mercado JE, Hoeflich KP, Su F, van Bruggen N et al (2012) FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res 2(1):22 Epub 20120531. https:\/\/doi.org\/10.1186\/2191-219x-2-22","journal-title":"EJNMMI Res"},{"key":"4896_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1479-5876-8-39","volume":"8","author":"JN S\u00f8ndergaard","year":"2010","unstructured":"S\u00f8ndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S et al (2010) Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032. J Transl Med 8:39 Epub 20100420. https:\/\/doi.org\/10.1186\/1479-5876-8-39","journal-title":"J Transl Med"},{"issue":"4","key":"4896_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2159-8290.Cd-13-0440","volume":"4","author":"TJ Parmenter","year":"2014","unstructured":"Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR et al (2014) Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov 4(4):423\u2013433 Epub 20140127. https:\/\/doi.org\/10.1158\/2159-8290.Cd-13-0440","journal-title":"Cancer Discov"},{"issue":"12","key":"4896_CR34","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1056\/NEJMoa022050","volume":"348","author":"IS Farooqi","year":"2003","unstructured":"Farooqi IS, Keogh JM, Yeo GSH, Lank EJ, Cheetham T, O\u2019Rahilly S (2003) Clinical spectrum of obesity and mutations in the Melanocortin 4 receptor gene. N Engl J Med 348(12):1085\u20131095. https:\/\/doi.org\/10.1056\/NEJMoa022050PubMed PMID: 12646665","journal-title":"N Engl J Med"},{"issue":"1","key":"4896_CR35","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/j.1471-4159.2009.06144.x","volume":"110","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Wu X, He Y, Kastin AJ, Hsuchou H, Rosenblum CI et al (2009) Melanocortin potentiates leptin-induced STAT3 signaling via MAPK pathway. J Neurochem 110(1):390\u2013399 Epub 20090505. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06144.x","journal-title":"J Neurochem"},{"key":"4896_CR36","doi-asserted-by":"publisher","unstructured":"Hustvedt BE, Lovo A (1972) Correlation between hyperinsulinemia and hyperphagia in rats with ventromedial hypothalamic lesions. Acta Physiol Scand.;84(1):29\u201333. https:\/\/doi.org\/10.1111\/j.1748-1716.1972.tb05152.x. PubMed PMID: 5029381","DOI":"10.1111\/j.1748-1716.1972.tb05152.x"},{"issue":"2","key":"4896_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1210\/jc.2002-021180","volume":"88","author":"RH Lustig","year":"2003","unstructured":"Lustig RH, Post SR, Srivannaboon K, Rose SR, Danish RK, Burghen GA et al (2003) Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab 88(2):611\u2013616. https:\/\/doi.org\/10.1210\/jc.2002-021180PubMed PMID: 12574189","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"4896_CR38","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1055\/s-2006-955086","volume":"38","author":"MC Amato","year":"2006","unstructured":"Amato MC, Elias LL, Elias J, Santos AC, Bellucci AD, Moreira AC et al (2006) Endocrine disorders in pediatric - onset Langerhans Cell histiocytosis. Horm Metab Res 38(11):746\u2013751. https:\/\/doi.org\/10.1055\/s-2006-955086PubMed PMID: 17111302","journal-title":"Horm Metab Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04896-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04896-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04896-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T22:12:25Z","timestamp":1739830345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04896-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["4896"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04896-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was registered as a service evaluation project by the Joint Research and Development Office for Great Ormond Street Hospital and UCL Great Ormond Street Institute of Child Health. No ethics approval was therefore required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Financial Interests: AHBJ had previously been employed by VineHealth a Medical Technology company contracted by Novartis to conduct research relating to Tafinlar (dabrafenib) and Mekinist (trametinib). AHBJ was not directly involved in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}